Biosimilars – How similar must they be?

28th April 2011

Category: Biosimilars

Tags: ,

By: Dr Daniel Galbraith, CSO

The hype over the market for biosimilars remains buoyant; research indicates that the market is likely to be worth almost USD$20 Billion by 2014. This increase is in some part driven by the major Asian players who have well over one third of the market. This push is in many ways due to the strong More

Coping with New Virus Risks in the Manufacture of Biologics

14th April 2011

Category: Biosafety

Tags: , ,

By: Dr Daniel Galbraith, CSO

In June 2009 a new virus was added to the growing list of agents found contaminating Chinese Hamster Ovary cells used in the manufacture of Biologics. Genzyme reported a contamination of CHO bioreactor with Vesivirus (subsequently named 2117); this was the third time such infection of a bioreactor had occurred in Genzyme. This virus which More

Sign-up to receive 3 tips on improving
speed to clinic for biosimilars

Sign-up to receive 3 tips on improving
speed to clinic for biosimilars

* you agree to receive emails with tips, news, insights and quizzes.